LL-37 Protocol — Complete Dosing & Administration Guide

Dosing

How muchdo I take?

Topical: Applied onto the skin as a cream, gel, or lotion — it works mainly where you put it.

Bioavailability Local — acts mainly at the skin; little reaches the bloodstream.

Starting Dose

0.5 mg/mL gel

Frequency

Twice weekly

Duration

4 weeks

Lowest dose in the LL-37 (ropocamptide) Phase I/IIa venous leg-ulcer trial and the most effective: ~6-fold faster healing and ~68% ulcer-area reduction vs placebo, applied to the wound twice weekly [4].

Standard Dose

1.6 mg/mL gel

Mid dose in the same trial; ~3-fold improvement and ~50% area reduction vs placebo. The highest tested concentration (3.2 mg/mL) showed no benefit over placebo, so dose escalation above this is not supported [4].

Timing

Best time to take

Apply LL-37 to clean, dry skin. For best results, use consistently at the same time(s) each day. Evening application is often preferred to allow overnight absorption, unless otherwise directed.

With food?

As a topical product, LL-37 is not affected by food intake. Apply to clean skin and allow adequate absorption time before covering the area.

If stacking

LL-37 should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

Adjusting Your Dose

Increase if

+You've tolerated the current dose for the recommended period without significant side effects

+Therapeutic goals haven't been met at the current dose level

+Your healthcare provider recommends dose escalation based on your response

+Lab work or clinical assessments support a higher dose

Decrease if

-Side effects are bothersome or impacting daily life despite management strategies

-You experience any signs of an adverse reaction

-Lab results indicate the need for dose reduction

-Your healthcare provider recommends a lower dose based on your response

Signs of right dose

✓Therapeutic goals being met with minimal side effects

✓Stable and consistent response to treatment

✓Lab values or clinical markers trending in the right direction

✓Good tolerance with manageable or absent side effects

Dosing Calculator

Calculate Your Exact Dose

Step 1: Peptide Weight

Find the weight printed on your peptide vial label

Look here!

The peptide weight is printed on the label

The weight is on the label

Select Weight

Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)

Administration

How do Iuse it?

Reconstitution

What you need

•LL-37 in its prescribed form

•Clean, dry storage container

•Measuring device if applicable (oral syringe, measuring cup)

•Calendar or reminder app for dosing schedule

Example

LL-37 comes in pre-measured doses or forms. Follow the exact dosing instructions on your prescription label. No reconstitution or mixing is typically required for this formulation.

Use LL-37 exactly as prescribed. Each unit contains the labeled amount. Your healthcare provider will determine the appropriate dose based on your individual needs and response.

Injection

Route

LL-37 is administered Topical application (wound healing)—no injection required

Best sites

•Not applicable—this is not an injectable formulation

Technique

1.Follow the specific administration instructions for your LL-37 formulation

2.Take or apply as directed by your healthcare provider

3.Store properly between uses according to package instructions

Storage

Before reconstitution

Store LL-37 in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

After reconstitution

Once reconstituted, LL-37 should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs of degradation

Solution appears cloudy, discolored, or contains visible particles (should be clear)

Product has been exposed to temperatures outside the recommended storage range

Product has been frozen (unless specifically designed for freeze-thaw stability)

Expiration date has passed or reconstituted solution has exceeded its use-by date

Unusual odor, color change, or visible contamination

Sample Daily Schedule

As prescribed (once daily)

As prescribed by your healthcare provider injection

Site: Topical application (wound healing)—rotate sites if applicable

Maintain a consistent schedule for optimal results with LL-37. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.

Safety

Is itsafe?

Safety Profile

LL-37 is an endogenous cathelicidin antimicrobial peptide naturally produced by immune cells and epithelial tissues, conferring inherent biocompatibility and low toxicity at physiological concentrations. Synthetic LL-37 shows excellent safety in in vitro immune assays and animal models with no hepatotoxicity, nephrotoxicity, or genotoxicity at relevant doses. At elevated concentrations, the cationic amphipathic structure can cause hemolysis and cell membrane damage, but therapeutic doses are far below these thresholds. Injection site reactions are minimal in research applications.

LL-37 safety derives from extensive basic research in immunology and dermatology journals (Nature Immunology, Journal of Immunology) demonstrating antimicrobial activity, wound healing promotion, and immune modulation without systemic toxicity. Human clinical data are limited—most applications remain in vitro or preclinical. Phase 1 safety and pharmacokinetics data suggest good tolerability, but Phase 2+ efficacy trials in infectious disease and skin conditions are ongoing. The peptide is generally recognized as safe for topical and research applications.

Common Side Effects

Experienced by some users

Local site irritation

Mild redness, warmth, or irritation at the wound application site. This is the most frequently reported adverse effect in clinical trials and reflects the peptide's interaction with wound-bed tissues.

Management: Generally self-limiting. If irritation is significant, reduce application frequency to every other day. Ensure wound is gently cleansed before application.

Transient stinging or burning

Brief stinging or burning sensation upon application to open wound surfaces, typically lasting seconds to minutes.

Management: Allow reconstituted solution to reach room temperature before application. Sensation typically diminishes with subsequent applications as wound healing progresses.

Mild perilesional erythema

Redness in the skin surrounding the treated wound area, reflecting local immune activation and increased blood flow from LL-37-induced angiogenesis.

Management: Usually indicates active healing response. Monitor for signs of infection versus expected inflammatory healing. Should remain localized and non-spreading.

Increased wound exudate

Temporary increase in wound fluid production during initial treatment phase as antimicrobial and pro-healing mechanisms activate.

Management: Use appropriate absorbent wound dressings. Typically normalizes within 1-2 weeks as healing progresses and bacterial bioburden is reduced.

Less Common

•Allergic contact reaction

These typically resolve with continued use or dose adjustment.

Stop and Seek Help If

×Severe or worsening side effects that don't improve with dose adjustment or supportive care

×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing

×Your healthcare provider recommends discontinuation based on your clinical response

×Development of any new medical condition that may be contraindicated with LL-37

×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)

×Abnormal lab results or clinical markers that suggest adverse effects

LL-37 should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

Interactions

With other peptides

✓May be used together under medical guidance.

With medications

!High-concentration saline solutions — elevated salt concentrations can reduce LL-37 antimicrobial activity through charge shielding effects - Use with caution—discuss with your healthcare provider.

!Anionic surfactants or dressings — may bind and inactivate the cationic LL-37 peptide through electrostatic complexation - Use with caution—discuss with your healthcare provider.

!Serum-rich wound environments without dose adjustment — serum proteins can partially sequester LL-37 and reduce effective concentration - Use with caution—discuss with your healthcare provider.

With supplements

✓Multivitamins - Generally safe to take alongside LL-37. Space doses apart if taking oral formulations to ensure optimal absorption.

✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Want the Full Picture?

View the complete LL-37 research profile including mechanism of action, clinical studies, effectiveness timeline, and FAQ.